Imiquimod, TLR7 ligand


Imiquimod, TLR7 ligand [NBP2-26228] - TLR7 stimulation with the measured by SEAP Expression 293T cells were transfected with pCMV/TLR7 plasmid and pNF-kB/SEAP plasmid using Lipofectamin 2000. After 48 hrs of more

Product Details

Reactivity Hu, MuSpecies Glossary
Applications Func, In vitro, LA
Please see the protocols for proper use of this product. If no protocol is available, contact technical services for assistance.

Order Details

Imiquimod, TLR7 ligand Summary

Imiquimod, TLR7 ligand is an imidazoquinoline amine analog to guanosine. As a synthetic molecule of the Imidazoquinoline family, it has potent immunostimulatory activity. Imiquimod has been shown to activate only TLR7. This activation is MyD88 dependant and leads to the induction of the transcription factor NF-kB.
Imiquimod is human/mouse TLR7 agonist.
Endotoxin Note
<0.001 EU/ug


Application Notes
Formula: C14H16N4, HCl Molecular weight: 276.8 This product is useful for Activation of TLR7 and stimulation of TLR7 has been achieved with 5-10 ug/ml. Use in Ligand activation, functional, and in vitro reported in scientific literature (PMID 25957979)
Reviewed Applications
Read 1 Review rated 5
NBP2-26228 in the following application:

Read Publications using
NBP2-26228 in the following applications:

Packaging, Storage & Formulations

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
NBP2-26228-.125mg: 125ug in 50 ul of DMSO (this product was formerly supplied in sterile water) NBP2-26228-1mg: 1 mg in 400 ul of DMSO.
Please see the protocols for proper use of this product. If no protocol is available, contact technical services for assistance.


5 mg size will be provided as 5x 1.0mg vials.


Imiquimod, TLR7 ligand, an imidazoquinoline amine analog to guanosine, is an immune response modifier with potent indirect antiviral activity. The antiviral activity of imiquimod was first shown in guinea pigs infected with herpes simplex virus [1]. Imiquimod is now an approved treatment for external genital warts caused by human papillomavirus infection. This low molecular synthetic molecule induces the production of cytokines such as IFN-Alpha. Unlike R848, Imiquimod activates only TLR7 but not TLR8 [2]. This activation is MyD88-dependent and leads to the induction of the transcription factor NF-kB [3].


This product is for research use only and is not approved for use in humans or in clinical diagnosis. Support products are guaranteed for 6 months from date of receipt.

Publications for Imiquimod, TLR7 ligand (NBP2-26228)(8)

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 5 applications: Flow-IC, Func, In vitro, LA, in-vitro.

Filter By Application
In vitro
All Applications
Filter By Species
All Species
Showing Publications 1 - 8 of 8.
Publications using NBP2-26228 Applications Species
Parthasarathy G, Philipp MT. Intracellular TLR7 is activated in human oligodendrocytes in response to Borrelia burgdorferi exposure. Neurosci. Lett. 2018 Feb 03 [PMID: 29408631] (Human) Human
Yabe-Wada T, Matsuba S, Takeda K et al. TLR signals posttranscriptionally regulate the cytokine trafficking mediator sortilin. Sci Rep. May 25 2016 [PMID: 27220277] (Func, In vitro, Human, Mouse) Func, In vitro Human, Mouse
Li Q, Ma Y, Li L et al. Flagellin influences the expression of a variety of important cytokines and chemokines without affecting the immune status of umbilical cord mesenchymal stem cells. Mol Med Rep 2015 Sep 01 [PMID: 26330280] (Func, in-vitro) Func, in-vitro
Nohmi K, Tokuhara D, Tachibana D et al. Zymosan Induces Immune Responses Comparable with Those of Adults in Monocytes, Dendritic Cells, and Monocyte-Derived Dendritic Cells from Cord Blood. J. Pediatr. 2015 May 06 [PMID: 25957979] (LA, Func, In vitro, Human)

Imiquimod, TLR7 ligand, ( Imgenex IMG-2207) was used for in-vitro stimulation experiments involving human heparinized cord or adult blood Monocytes, peripheral blood dendritic cells (DCs) and monocyte-derived DCs (MoDCs). Imiquimod was employed at 0.5 ug/mL concentration on Monocytes as well as on MoDCs and at 0.25 ug/mL on DCs. See full text for experimental details and results.
LA, Func, In vitro Human
Zhang L, Liu D, Pu D et al. The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells Biological Research. 2015 Jan 17 [PMID: 25654296] (Human)

Imiquimod, TLR7 ligand used for stimulating human umbilical cord mesenchymal stem cells (UCMSCs) in experiments involving study of the immunogenicity of MSCs- Imiquimod dissolved in DMSO at 2.5 mg/ml concentration to make a stock solution and then added the stock solution to 6 wells plates containing 1.5 x 10(5) cells in 2 ml medium at 10 ug/ml working concentration. Experiments also involved Imiquimod treatment to co-cultures of PBMC and UCMSC.
Valencia Pacheco GJ, Pinzon Herrera F, Cruz Lopez JJ et al. Expression and activation of intracellular receptors TLR7, TLR8 and TLR9 in peripheral blood monocytes from HIV-infected patients. Colomb Med (Cali). 2013 Jun 30 [PMID: 24892454] (Flow-IC)

TLR7 Ligand (IMG-2207), TLR9 Ligand (IMG-2209Hpt), IC-Flow (Intracellular Staining Flow Assay) Kit (10083K).
Kusagaya H, Fujisawa T, Yamanaka K et al. Toll-like receptor-mediated airway IL-17C enhances epithelial host defense in an autocrine/paracrine manner. Am. J. Respir. Cell Mol. Biol. 2014 Jan 1 [PMID: 23944933] (In vitro, Human)

TLR ligand treatment (primary normal human bronchial epithelial cells), Figs 1, S1. CpG-ODN was used at 10 ug/ml.
In vitro Human
Gillaux C, Mehats C, Vaiman D et al. Functional screening of TLRs in human amniotic epithelial cells. J Immunol. 2011 Sep 1 [PMID: 21775685]

Products cited: TLR ligands: TLR1/2 (IMG-2201), TLR3 (IMG-2203), TLR4 (IMG-2204), TLR5 (IMG-2205), TLR6/2 (IMG-2206), TLR7 (IMG-2207), TLR9 (IMG-2209Hpt). The effects of ligand stimulation was measured by various readout assays, refer to the figures for d

Review for Imiquimod, TLR7 ligand (NBP2-26228) (1) 51

Average Rating: 5
(Based on 1 review)

Reviews using NBP2-26228:
Filter by Applications
All Applications
Filter by Species
All Species
Images Ratings Applications Species Date Details
Immunocytochemistry/Immunofluorescence Imiquimod, TLR7 ligand NBP2-26228
reviewed by:
ICC/IF 08/15/2017




CommentsImiquimod was added into the medium at final concentration
of 10 μg/ml. Imiquimod enhanced the osteo-differentiation ability of mesenchymal stem cells.

FAQs for Imiquimod, TLR7 ligand (NBP2-26228) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional Array Products

Blogs on Imiquimod, TLR7 ligand

There are no specific blogs for Imiquimod, TLR7 ligand, but you can read our latest blog posts.

Contact Information

Product PDFs

Recent Reviews


Application: ICC/IF